TORG
20.8.2021 11:29:08 CEST | Business Wire | Press release
Cryptocurrencies seem to be the flavour of the season as increasingly more people around the world are embracing them; sometimes even abandoning their traditional avenues like Equity, Gold, etc. Though the concept of crypto (as they are informally called) investment seems novel, the first cryptocurrency came into the market more than a decade back. The reliable supply, decentralised control, swift success, and exorbitant returns given by cryptocurrencies have now allayed all fears of them being a ‘fad’ or even a ‘sham’. Today, you have many different options of cryptocurrencies trading on different real-time online platforms.
Though, as the cryptocurrencies do not have any underlying asset to base your buying or selling decision upon (for example – Google shares move on the performance of the Google companies), all the cryptocurrencies on the face look similar. But, one cryptocurrency, recently launched, is destined to change all that, and is already making waves around the world as people are lapping it up in droves.
TORG is the world’s first sustainability driven, completely decentralized, and utility-focused cryptocurrency, aimed at global human development. If it sounds confusing, it’s because it’s such a new concept. As the world’s first utilimeme, it combines the power of meme-driven popularity with the sustainability that comes with a focus on global utility.
Launched recently on 20th July 2021, TORG has already reached the maximum supply of 777 billion and its current circulating supply is 100%. TORG is secured as an ERC-20 token on the Ethereum blockchain. It is not open to pausing, minting, and mining. Being extremely secure and stable, TORG’s smart contract is audited by the best in the industry blockchain security and infrastructure leader Certik.
TORG started trading from 20th July 2021 on world’s leading Global Exchanges, namely Uniswap , BitMart , CoinTiger , ProBit , CoinsBit Global , CoinsBit India , WhiteBit , HotBit.io , LA Token , IndoEx International , Bilaxy , etc. It is expanding its reach rapidly and is expected to be available on many trading platforms, big & small, shortly. Since the launch, different pairs of TORG have been added by the centralized exchanges, including TORG/USDT, TORG/BTC, and TORG/ETH .
TORG – It is different, but is it better?
What makes TORG better than other cryptocurrencies is the same thing that makes the world a better place to live in, i.e. focus on sustainability. TORG is not just any regular cryptocurrency. It is the world’s first cryptocurrency that has sustainability & utility as its underlying core assets. It aims to increase commercial & business activities, generate growth & employment opportunities for the world’s youth, develop eco-friendly infrastructure around the world, push the population to adopt green initiatives, and alleviate the economic constraints facing the world’s marginalized demographic sections.
About TORG
TORG Foundation is the force behind this intuitive & innovative cryptocurrency that aims to disrupt the crypto market forever. With the mission & vision of helping the society keep its carbon footprint to the minimum while increasing the economic activities both in developing & developed countries for the holistic development of mankind, the foundation keeps the interests of humanity and mankind at the core of all its decisions.
To maintain the full transparency of transactions, TORG is completely decentralised, and the foundation does not & cannot decide or predict its price movements.
It’s #TORGTime.
For more information and updates, visit www.torg.to or follow TORG on Twitter , Telegram , Facebook , and Medium .
Disclaimer: The information available on this article is for educational purposes only and not an offer, solicitation of an offer, or advice to buy or sell securities, investment or tax advice. Purchasing cryptocurrencies comes with a number of risks. All Forward-looking statements involve risks and uncertainties which may cause actual results to differ materially from the statements made here. The data and non-TORG names are for informational and identification purposes only.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210820005103/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
